In order to apply potent therapeutic protein factors to the central nervous system, it has become evident that direct brain delivery of a relevant factor in a distinct anatomical area is necessary to achieve therapeutic effects. Local cell based delivery of a neurotrophic factor has thus formed a clear product concept for NsGene. NsGene’s proprietary Encapsulated Cell (EC) biodeliveryTM system combines the efficacy of local cell-based synthesis and delivery with the safety and manufacturability of a medical device.
Based on the EC biodeliveryTM technology, NsGene develops EC BiodeliveryTM products for neurological diseases including Alzheimer’s disease (NsG0202), intractable epilepsy (NsG0501). In addition hereto, a number of EC BiodeliveryTM products for other indications are under investigation.
Factor Discovery Engine
To fuel the product pipeline, NsGene has generated a factor pipeline of neurotrophic proteins, which have the potential to become novel CNS therapeutics that can be administered to patients as an EC Biodelivery™ product or as an injectable protein formulation. These proteins has been identified in NsGene's Factor Discovery Engine which cornerstone has been the Center for Biological Sequence Analysis at Danish Technical University led by prof. Søren Brunak. NsGene has exploited novel neurotrophic factors by state-of-the-art facilities for cloning of genes and cDNAs, ELISA and protein purification, generation of lenti- og retroviral vectors for functional expression studies and functional testing of discovered genes in relevant in vitro and in vivo models. In addition NsGene has designed a large tissue compendium covering most areas of the developing brain which is used for detailed quantitative expression profiling of novel genes.
